Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial

British Journal of Haematology
Stephan FuhrmannRichard Ratei

Abstract

This study reports the prognostic impact of the expression of the natural killer cell marker CD56 in a large series of risk-adapted paediatric patients with T cell acute lymphoblastic leukaemia (T-ALL; n = 493) treated within the ALL-Berlin-Frankfurt-Münster (BFM) 2000 protocol. The immunophenotype was analysed centrally at diagnosis using flow cytometry and correlated with clinical parameters and outcome. CD56 expression was detected in 7·1% and early T-cell precursor (ETP) phenotype in 6·7% of all T-ALL patients. The percentage of ETP in the CD56+ T-ALL cohort was 4-fold higher than in the whole cohort. CD56+ T-ALL frequently expressed the progenitor marker CD34 and myeloid antigens CD13 and CD33. The 5-year event-free survival (EFS) rates for the European Group for the Immunological classification of Leukaemias/World Health Organization subgroups and the ETP phenotype were not statistically different. By contrast, patients with CD56 expression had a significantly reduced EFS (60 ± 8%) and overall survival (60 ± 8%) at 5 years, with a hazard ratio of 2·46 (P = 0·002) and 2·99 (P < 0·001), respectively. Moreover, CD56 expression in combination with the minimal residual disease (MRD)-based high risk assignment defined a populat...Continue Reading

References

Apr 3, 2001·American Journal of Hematology·E PaiettaUNKNOWN Eastern Cooperative Oncology Group
Jan 17, 2009·The Lancet Oncology·Elaine Coustan-SmithDario Campana
Oct 26, 2010·Immunological Reviews·Roel G J Klein WolterinkJames P Di Santo
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Jul 12, 2011·Annual Review of Cell and Developmental Biology·Ute Koch, Freddy Radtke
Jan 25, 2017·Blood·Tiziana GirardiKim De Keersmaecker

❮ Previous
Next ❯

Citations

Nov 12, 2019·Expert Review of Molecular Diagnostics·Maria Ilaria Del PrincipeAdriano Venditti
Nov 18, 2018·Current Hematologic Malignancy Reports·Franklin Fuda, Weina Chen
Feb 3, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Olga K WeinbergRobert P Hasserjian
Dec 27, 2019·Journal of Pediatric Hematology/oncology·Masanori AokiYasuhiro Ebihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.